Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
Center for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Cytotherapy. 2022 Aug;24(8):850-860. doi: 10.1016/j.jcyt.2022.03.014. Epub 2022 May 25.
Lentiviral vectors (LVs) have been used extensively in gene therapy protocols because of their high biosafety profile and capacity to stably express a gene of interest. Production of these vectors for the generation of chimeric antigen receptor (CAR) T cells in academic and research centers is achieved using serum-supplemented static monolayer cultures. Although efficient for pre-clinical studies, this method has a number of limitations. The main hurdles are related to its incompatibility with robust and controlled large-scale production. For this reason, cell suspension culture in bioreactors is desirable. Here the authors report the transition of LV particle production from serum-supplemented monolayer to serum-free suspension culture with the objective of generating CAR T cells.
A self-inactivating LV anti-CD19 CAR was produced by transient transfection using polyethylenimine (PEI) in human embryonic kidney 293 T cells previously adapted to serum-free suspension culture.
LV production of 8 × 10 transducing units (TUs)/mL was obtained in serum-supplemented monolayer culture. LV production in the serum-free suspension conditions was significantly decreased compared with monolayer production. Therefore, optimization of the transfection protocol was performed using design of experiments. The results indicated that the best condition involved the use of 1 μg of DNA/10 cells, 1 × 10 cells/mL and PEI:DNA ratio of 2.5:1. This condition used less DNA and PEI compared with the standard, thereby reducing production costs. This protocol was further improved with the addition of 5 mM of sodium butyrate and resulted in an increase in production, with an average of 1.5 × 10 TUs/mL. LV particle functionality was also assessed, and the results indicated that in both conditions the LV was capable of inducing CAR expression and anti-tumor response in T cells, which in turn were able to identify and kill CD19+ cells in vitro.
This study demonstrates that the transition of LV production from small-scale monolayer culture to scalable and controllable bioreactors can be quite challenging and requires extensive work to obtain satisfactory production.
慢病毒载体(LVs)因其高生物安全性和稳定表达目的基因的能力而被广泛应用于基因治疗方案中。在学术和研究中心中,为了生成嵌合抗原受体(CAR)T 细胞,这些载体是通过添加血清的静态单层培养来生产的。尽管这种方法对于临床前研究非常有效,但它存在许多局限性。主要障碍与它与强大且可控的大规模生产不兼容有关。出于这个原因,需要在生物反应器中进行细胞悬浮培养。作者在此报告了从添加血清的单层培养到无血清悬浮培养的 LV 颗粒生产的转变,目的是生成 CAR T 细胞。
通过使用聚乙二醇化亚精胺(PEI)在先前适应于无血清悬浮培养的人胚肾 293 T 细胞中转染,产生了一种自我失活的抗 CD19 CAR 的 LV。
在添加血清的单层培养中获得了 8×10 转导单位(TU)/mL 的 LV 产量。与单层培养相比,无血清悬浮条件下的 LV 产量显著下降。因此,通过实验设计优化了转染方案。结果表明,最佳条件涉及使用 1μg DNA/10 个细胞、1×10 个细胞/mL 和 2.5:1 的 PEI:DNA 比例。与标准相比,该条件使用的 DNA 和 PEI 更少,从而降低了生产成本。通过添加 5 mM 丁酸钠进一步改进了该方案,导致产量增加,平均达到 1.5×10 TU/mL。还评估了 LV 颗粒的功能,结果表明,在这两种条件下,LV 都能够诱导 CAR 表达和 T 细胞的抗肿瘤反应,而 T 细胞反过来又能够识别和杀伤体外的 CD19+细胞。
这项研究表明,从小规模单层培养到可扩展和可控的生物反应器的 LV 生产的转变可能极具挑战性,需要进行广泛的工作才能获得令人满意的产量。